CoChat

Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo

Open access
Dacquin, Romain, Davey, Rachel A., Laplace, Catherine, Levasseur, Régis, Morris, Howard A., Goldring, Steven R., Gebre-Medhin, Samuel, Galson, Deborah L., Zajac, Jeffrey D., Karsenty, Gérard · 2004 · The Journal of Cell Biology

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Amylin is a member of the calcitonin family of hormones cosecreted with insulin by pancreatic β cells. Cell culture assays suggest that amylin could affect bone formation and bone resorption, this latter function after its binding to the calcitonin receptor (CALCR). Here we show that Amylin inactivation leads to a low bone mass due to an increase in bone resorption, whereas bone formation is unaffected. In vitro, amylin inhibits fusion of mononucleated osteoclast precursors into multinucleated osteoclasts in an ERK1/2-dependent manner. Although Amylin +/− mice like Amylin-deficient mice display a low bone mass phenotype and increased bone resorption, Calcr +/− mice display a high bone mass due to an increase in bone formation. Moreover, compound heterozygote mice for Calcr and Amylin inactivation displayed bone abnormalities observed in both Calcr +/− and Amylin +/− mice, thereby ruling out that amylin uses CALCR to inhibit osteoclastogenesis in vivo. Thus, amylin is a physiological regulator of bone resorption that acts through an unidentified receptor.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1083/jcb.200312135

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Low bone mass in Amy lin-deficient mice. (A) Body weight, gonadal fat pad weight, and food intake are identical between Amylin-deficient and wild-type (WT) mice. (B) X-ray analysis showing a decrease in mineral density in 6-mo-old Amylin-deficient compared with WT femurs. (C) Histological analysis of 6-mo-old WT and Amylin-deficient vertebrae showing a decrease in bone volume over tissue volume (BV/TV). (D) Low bone mass phenotype in both male and female Amylin-deficient mice. (E–G) Microarchitecture parameters in Amylin-deficient mice. Cortical thickness (E), trabecular thickness (F), and number of nodes (G) were decreased in Amylin-deficient compared with WT mice. (H) Bone mass of 6-, 12-, and 24-wk-old WT and Amylin-deficient mice vertebrae. Asterisks indicate statistically significant differences (t ≤ 0.01) between two groups (n ≥ 8). Error bars represent SEM.
Figure 1. Low bone mass in Amy lin-deficient mice. (A) Body weight, gonadal fat pad weight, and food intake are identical between Amylin-deficient and wild-type (WT) mice. (B) X-ray analysis showing a decrease in mineral density in 6-mo-old Amylin-deficient compared with WT femurs. (C) Histological analysis of 6-mo-old WT and Amylin-deficient vertebrae showing a decrease in bone volume over tissue volume (BV/TV). (D) Low bone mass phenotype in both male and female Amylin-deficient mice. (E–G) Microarchitecture parameters in Amylin-deficient mice. Cortical thickness (E), trabecular thickness (F), and number of nodes (G) were decreased in Amylin-deficient compared with WT mice. (H) Bone mass of 6-, 12-, and 24-wk-old WT and Amylin-deficient mice vertebrae. Asterisks indicate statistically significant differences (t ≤ 0.01) between two groups (n ≥ 8). Error bars represent SEM.CC BY-NC-SA · PubMed Central
Figure 2. Increased bone resorption in Amylin-deficient mice. (A and B) Calcein double labeling in 6-mo-old WT and Amylin-deficient mice. The bone formation rate (BFR) is not affected in Amylin-deficient mice nor is the number of osteoblasts. (C) Urinary deoxypyridinoline cross-links elimination was significantly increased in Amylin-deficient compared with WT mice at 8, 12, and 24 wk old. (D) Increased number of TRAP-positive multinucleated osteoclasts in Amylin-deficient compared with WT bones. Note the thinner appearance of the trabeculae. (E) Increased TRAP-positive surface per bone perimeter in Amylin-deficient compared with WT osteoclasts. Asterisks indicate statistically significant differences (t ≤ 0.01) between two groups (n ≥ 8). Error bars represent SEM.
Figure 2. Increased bone resorption in Amylin-deficient mice. (A and B) Calcein double labeling in 6-mo-old WT and Amylin-deficient mice. The bone formation rate (BFR) is not affected in Amylin-deficient mice nor is the number of osteoblasts. (C) Urinary deoxypyridinoline cross-links elimination was significantly increased in Amylin-deficient compared with WT mice at 8, 12, and 24 wk old. (D) Increased number of TRAP-positive multinucleated osteoclasts in Amylin-deficient compared with WT bones. Note the thinner appearance of the trabeculae. (E) Increased TRAP-positive surface per bone perimeter in Amylin-deficient compared with WT osteoclasts. Asterisks indicate statistically significant differences (t ≤ 0.01) between two groups (n ≥ 8). Error bars represent SEM.CC BY-NC-SA · PubMed Central
Figure 3. Amylin inhibits osteoclastogenesis ex vivo. (A) In vitro differentiation of osteoclasts is inhibited by amylin at a physiological concentration (10−10 M). (B) Multinucleated osteoclasts differentiating in the presence of amylin are smaller and have fewer of nuclei. (C) BMMs proliferation and early steps of osteoclast differentiation was not affected by amylin. (•) 10−10 M amylin; (▴) vehicle. (D) Dentine slice resorption assay in the presence of vehicle or physiological levels of amylin. Resorption is decreased by the presence of amylin in a manner proportional to the decrease in the number of osteoclasts. (E) In vitro differentiation of ERK1/2 dominant negative infected and noninfected osteoclasts in presence of amylin. ERK1/2 is phosphorylated 5 min after stimulation by amylin in noninfected culture, whereas this phosphorylation is abolished in ERK1/2 dominant negative infected cells. (F) Amylin inhibition of osteoclastogenesis is abolished in ERK1/2 dominant negative infected culture. Error bars represent SEM. The asterisks indicate a statistical difference (t ≤ 0.05) between vehicle and treated culture.
Figure 3. Amylin inhibits osteoclastogenesis ex vivo. (A) In vitro differentiation of osteoclasts is inhibited by amylin at a physiological concentration (10−10 M). (B) Multinucleated osteoclasts differentiating in the presence of amylin are smaller and have fewer of nuclei. (C) BMMs proliferation and early steps of osteoclast differentiation was not affected by amylin. (•) 10−10 M amylin; (▴) vehicle. (D) Dentine slice resorption assay in the presence of vehicle or physiological levels of amylin. Resorption is decreased by the presence of amylin in a manner proportional to the decrease in the number of osteoclasts. (E) In vitro differentiation of ERK1/2 dominant negative infected and noninfected osteoclasts in presence of amylin. ERK1/2 is phosphorylated 5 min after stimulation by amylin in noninfected culture, whereas this phosphorylation is abolished in ERK1/2 dominant negative infected cells. (F) Amylin inhibition of osteoclastogenesis is abolished in ERK1/2 dominant negative infected culture. Error bars represent SEM. The asterisks indicate a statistical difference (t ≤ 0.05) between vehicle and treated culture.CC BY-NC-SA · PubMed Central
Figure 4. Different bone phenotypes in Amylin +/− and Ca lcr +/− mice. (A) Targeted disruption of Calcr (arrowheads represent primers). (B) PCR analysis using primers specific for the targeted construct confirming efficient recombination at the Calcr locus. (C) Presence of the Calcr targeted allele was assessed by PCR. (D) Decreased Calcr expression in Calcr +/− compared with WT osteoclasts as measured by real time PCR. (E) Bone volume over tissue volume (BV/TV) is increased in Calcr +/−, decreased in Amylin +/− (Am +/−) mice, and increased in Am +/−; Calcr +/− mice compared with WT littermates. (F) Osteoclasts number per bone perimeter is normal in Calcr +/− mice and increased in both Amylin +/− and Am +/−; Calcr +/− compared with WT mice. (G) BFR is increased in Calcr +/−, and Am +/−; Calcr +/− mice, whereas it is normal in Amylin +/− mice. Asterisks indicate statistically significant differences (t ≤ 0.01) between WT and mutant mice (n ≥ 6). Error bars represent SEM.
Figure 4. Different bone phenotypes in Amylin +/− and Ca lcr +/− mice. (A) Targeted disruption of Calcr (arrowheads represent primers). (B) PCR analysis using primers specific for the targeted construct confirming efficient recombination at the Calcr locus. (C) Presence of the Calcr targeted allele was assessed by PCR. (D) Decreased Calcr expression in Calcr +/− compared with WT osteoclasts as measured by real time PCR. (E) Bone volume over tissue volume (BV/TV) is increased in Calcr +/−, decreased in Amylin +/− (Am +/−) mice, and increased in Am +/−; Calcr +/− mice compared with WT littermates. (F) Osteoclasts number per bone perimeter is normal in Calcr +/− mice and increased in both Amylin +/− and Am +/−; Calcr +/− compared with WT mice. (G) BFR is increased in Calcr +/−, and Am +/−; Calcr +/− mice, whereas it is normal in Amylin +/− mice. Asterisks indicate statistically significant differences (t ≤ 0.01) between WT and mutant mice (n ≥ 6). Error bars represent SEM.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Research works printed but not linked: 4

  1. 1998, Am. J. Physiol., 275, E694
  2. 1995, Endocrinology., 136, 4572, 10.1210/endo.136.10.7664679 · doi:10.1210/endo.136.10.7664679 · Paper page
  3. 1992, Endocrinology., 131, 1497, 10.1210/endo.131.3.1324163 · doi:10.1210/endo.131.3.1324163 · Paper page
  4. 1987, Am. J. Pathol., 127, 414

Cited by

See all 210

Metadata

Authors
Dacquin, R., Davey, R. A., Laplace, C., Levasseur, R., Morris, H. A., Goldring, S. R., Gebre-Medhin, S., Galson, D. L., Zajac, J. D., & Karsenty, G.
Affiliations
  • Baylor College of Medicine (US)
  • The University of Melbourne (AU)
  • Beth Israel Deaconess Medical Center (US)
  • 1Department of Molecular and Human Genetics and Bone Disease Program of Texas, Baylor College of Medicine, Houston, TX 77030
  • Hanson Institute (AU)
  • 5Department of Clinical Genetics, Lund University Hospital, SE-221 85, Lund, Sweden
Venue
The Journal of Cell Biology
Published
2004-02-16
Volume
164
Issue
4
Pages
509-514
ISSN
  • 0021-9525 (ISSN-L)
  • 1540-8140
OpenAlex
W2108642017
Cited by
206
References
25
Citations by year
2026: 7 · 2025: 3 · 2024: 4 · 2023: 6 · 2022: 2 · 2021: 8 · 2020: 7 · 2019: 11 · 2018: 8 · 2017: 5 · 2016: 7 · 2015: 10 · 2014: 12 · 2013: 7 · 2012: 11
FWCI
5.10
Type
journal article
Language
en
Open access
Locations
  • The Journal of Cell Biology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK058883, R01-DK58883)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01-AR45421, R01AR045421)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Bone and Dental Protein Studies
Keywords
amylin, calcitonin receptor, bone resorption, bone formation, osteoclastogenesis, osteoclast precursors, ERK signaling, osteopenia, bone metabolism regulation
MeSH terms
Amyloid, Animals, Bone and Bones, Bone Resorption, Cell Differentiation, Mice, Inbred C57BL, Osteoclasts, Osteogenesis, Phenotype, Bone Density, Receptors, Calcitonin, Mice, Knockout, Mitogen-Activated Protein Kinases, Mice, Islet Amyloid Polypeptide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. https://app.cochat.ai/papers/10.1083/jcb.200312135
The paper
Dacquin, R., Davey, R. A., Laplace, C., Levasseur, R., Morris, H. A., Goldring, S. R., Gebre-Medhin, S., Galson, D. L., Zajac, J. D., & Karsenty, G. (2004). Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. The Journal of Cell Biology. https://doi.org/10.1083/jcb.200312135

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.